Senti Bio Appoints Fran Schulz to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
December 4, 2024 6:54 AM ESTChardan Capital Markets analyst Geulah Livshits raised the price target on Senti Biosciences, Inc. (NASDAQ: SNTI) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "On 3 December, Senti Biosciences hosted a call to discuss initial data from the phase I trial of its... More
